Radio ExpressTV
Live
“The New Pharmaceuticals Law: A Step Towards Health Sovereignty or Just a Procedural Reform?”
In light of the significant changes occurring in Morocco’s healthcare sector, the proposed law to amend Law No. 17.04, which serves as the Pharmaceutical Code, stands out as one of the key legislative initiatives that the state is banking on to enhance health security and establish pharmaceutical sovereignty. This initiative is not without precedent; it is part of a strategic vision led by His Majesty King Mohammed VI, aimed at strengthening the autonomy of the healthcare system and ensuring citizens have access to safe, effective, and high-quality medications.
This legislative measure reflects a growing awareness of the importance of controlling the production and distribution chains of pharmaceuticals, especially after the harsh lessons brought on by the COVID-19 pandemic, which exposed the vulnerabilities of many healthcare systems around the world, including those heavily reliant on imports. Consequently, Morocco aims to shift from a short-term crisis management approach to building a resilient pharmaceutical system.
Among the key objectives of this initiative is the country’s desire to enhance its position within the global health framework, particularly by aligning its legislation with the standards set by the World Health Organization. The inclusion of the Moroccan Agency for Medicines and Health Products in the list of entities that have reached advanced stages of regulatory maturity (level three or four) is not only an international recognition of the efficiency of Morocco’s regulatory system, but also a gateway to strategic partnerships, foreign investments, and opportunities to export pharmaceuticals to new markets.
Internally, the project aims to foster a qualitative shift in the regulation of the pharmaceutical sector by updating the licensing conditions for marketing drugs and promoting transparency in the granting processes, which will reduce bureaucracy while ensuring the safety of marketed products. It also places special emphasis on a drug vigilance system by establishing more sophisticated mechanisms for monitoring and tracking side effects, thereby enhancing the protection of public health and increasing trust in the healthcare system.
Important among its features is the strengthening of market surveillance mechanisms, both before and after drugs are marketed, along with expanding the powers of pharmacy inspections, in a bid to tackle illegal practices more stringently, including the promotion of counterfeit or substandard drugs. The project also grants more flexibility to the relevant authorities in dealing with exceptional situations, such as pandemics and disasters, allowing for expedited procedures to ensure the timely provision of medications.
However, despite its ambitious legislative goals, this initiative raises several fundamental questions. The success of any legal reform hinges on the effectiveness of its implementation in practice. Does the administration possess the sufficient human and technical resources to activate the provisions for monitoring and inspection? Will this initiative directly impact drug prices, which remain a daily concern for many Moroccans? Furthermore, to what extent can the national pharmaceutical industry adapt to and benefit from these changes amidst fierce competition from multinational companies?
At its core, the Pharmaceuticals Law is not merely a technical amendment to an existing legal text; it embodies a commitment to build a more autonomous and efficient health model. Yet, the real challenge lies not just in the quality of the texts, but in the ability to translate them into tangible public policies that directly affect citizens’ lives.
Between the ambition for health sovereignty and the realities of challenges, this initiative remains a true test of Morocco’s ability to win the battle for pharmaceuticals, not just as a product, but as a fundamental right for every citizen.
